-
Mashup Score: 5Illumina’s embrace of long-read technology signals a shift in the DNA-sequencing market - 2 year(s) ago
Some scoffed at Illumina’s prospects of rivaling existing players, while others think Infinity could help the company hold onto its customers. All agreed that the DNA sequencing market is shifting to longer reads.
Source: STATCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 0Stephen Parodi, MD, says regulatory flexibilities are needed for virtual care - Permanente Medicine - 2 year(s) ago
The Permanente Federation executive vice president tells J.P. Morgan panel that waivers allowing shifts in care delivery from in-person to virtual now face a “regulatory cliff.”
Source: Permanente MedicineCategories: General Medicine News, Latest HeadlinesTweet-
Permanente physician leader @StephenParodiMD recently told a #JPM22 Washington update panel that regulatory flexibilities are needed to support ongoing virtual #healthcare delivery. https://t.co/SVrXTxY4bd @jpmorgan #PermMedLeads
-
-
Mashup Score: 1
Bristol CEO Giovanni Caforio sat down with STAT to discuss his company’s outlook and plans for more business development, including acquisitions.
Source: STATCategories: General Medicine News, Latest HeadlinesTweet-
Fresh off a presentation at #JPM22, Bristol CEO Giovanni Caforio sat down with STAT to discuss his company’s outlook and plans for more business development, including acquisitions. https://t.co/T91F3fdC9i
-
-
Mashup Score: 0Home | Fierce JPM Week - 2 year(s) ago
We might have thought the COVID-19 pandemic would be over by year-end 2021, but experts now say—and the omicron variant suggests—the virus will likely always be with us. What pandemic lessons has the industry learned that can help tackle longtime challenges—such as speeding up drug development, adding new diversity into clinical trials, launching new products and, of course,…
Source: www.fiercejpmweek.comCategories: Future of Medicine, Latest HeadlinesTweet-
The #JPM22 conversations continue this week with our virtual #FierceJPMWeek Jan. 18-20. Find the lineup and sign up here: https://t.co/ZDeKBKHoee
-
-
Mashup Score: 0Home | Fierce JPM Week - 2 year(s) ago
We might have thought the COVID-19 pandemic would be over by year-end 2021, but experts now say—and the omicron variant suggests—the virus will likely always be with us. What pandemic lessons has the industry learned that can help tackle longtime challenges—such as speeding up drug development, adding new diversity into clinical trials, launching new products and, of course,…
Source: www.fiercejpmweek.comCategories: General Medicine News, Latest HeadlinesTweet-
The #JPM22 conversations continue this week with our virtual #FierceJPMWeek Jan. 18-20. Find the lineup and sign up here: https://t.co/IWlWdtkAI0
-
-
Mashup Score: 0JPM 2022: Talkspace faces securities fraud class-action suit as consumer revenue declines - 2 year(s) ago
Following a mass exodus of leadership that caused its shares to drop 36% in a week, virtual behavioral health company Talkspace now faces a securities fraud class-action lawsuit. The suit alleges the company failed to disclose certain growth headwinds before it went public last June.
Source: FierceHealthcareCategories: General Medicine News, Latest HeadlinesTweet-
#JPM22 @talkspace faces securities fraud class-action suit as consumer revenue declines https://t.co/lK73T6pcBX
-
#JPM22 @talkspace faces securities fraud class-action suit as consumer revenue declines https://t.co/06S4S8VzUA
-
-
Mashup Score: 1
Was J.P. Morgan a drag? Is it time to give up on Aduhelm? And how many guitars is too many? All that and more on the lastest episode of “The Readout LOUD.” Listen now:
Source: STATCategories: General Medicine News, Latest HeadlinesTweet-
A new episode of "The Readout LOUD" #podcast is here! This week the team tackles #JPM22 in review, Biogen’s worsening fortunes, the future of RNA drugs, and much more! Listen here: https://t.co/dHduvjbKU4
-
-
Mashup Score: 0Telehealth experiments & the latest digital health news from JPM - 2 year(s) ago
In the latest edition of STAT Health Tech: telehealth experiments, the latest from #JPM22, and the case for scaling primary care.
Source: STATCategories: Healthcare Professionals, Latest HeadlinesTweet-
Telehealth experiments & the latest digital health news from JPM #jpm22 https://t.co/0Zg4DWkaEP
-
-
Mashup Score: 1JPM 2022: Boston Scientific, Inspire, Nuvasive, Vericel - 2 year(s) ago
The annual J.P. Morgan Healthcare Conference includes presentations from major medtech companies describing their experience in 2021 and expectations for 2022 as they continue to cope with the impact of the Omicron surge. Here are some of the highlights from the presentations on the third day of the meeting.
Source: Medtech InsightCategories: Healthcare Professionals, Latest HeadlinesTweet-
RT @medtechMarion: JPM 2022: Boston Scientific, Inspire, Nuvasive, Vericel https://t.co/rWnktFRXY1 #JPM22 #JPM2022 #digitalhealth #orthpedi…
-
-
Mashup Score: 3Reporter's notebook: J.P. Morgan's 2022 health conference - 2 year(s) ago
Day 3 highlights include how Transcarent reached unicorn status in record time and Quest Diagnostics’ future plans.
Source: Modern HealthcareCategories: General Medicine News, Latest HeadlinesTweet-
RT @ntepper90: How Transcarent achieved unicorn status in record time 🦄💴🏃♀️ https://t.co/5qVuG5GQph via @modrnhealthcr #JPM22 #healthcare
-
Gene-sequencing giant Illumina announced during this year’s #JPM22 that it plans to roll out a new technology in the latter half of 2022, dubbed Infinity, which will read DNA in far larger chunks than the firm has ever tackled before. https://t.co/XGVR0R6K9a